# Novavax Inc. (NVAX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $10.22, market value $1.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Novavax Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 4.1×**. Each dollar of revenue is priced at 4.1×.

## Profitability
- **Operating margin: -56.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 39.2%**. 39.2% of each dollar of sales reaches the bottom line.
- **Return on equity: -344.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 149.0%**. Return on all capital, debt included, is 149.0%: comfortably above what that capital costs.
- **Return on assets: -21.1%**. Each dollar of assets produces -21.1% of profit.

## Growth
- **Revenue growth (1 yr): 64.7%** (3-yr -17.2%/yr, 5-yr 18.8%/yr). Revenue grew 64.7% over the last year, against 18.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 309.8%**. Earnings per share rose 309.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: net cash**. Novavax Inc. holds more cash than debt.
- **Altman Z-score: 2.85**. A Z-score of 2.85 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Novavax Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 31.2%** (YTD 52.1%, 3-mo 7.7%). The shares are up 31.2% over twelve months including dividends.
- **From 52-week high: -14.6%** (64.8% above the low). Trading 15% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 71**. An RSI of 71 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 1.91** (volatility 64%). Beta of 1.91 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NVAX · Page: https://foliofundamentals.com/stocks/nvax

Not investment advice.